https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Developing chemotherapeutics which disable the actin cytoskeleton of melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13243 Sat 24 Mar 2018 08:17:36 AEDT ]]> Targeting anti-apoptotic mechanisms for reversal of resistance to BRAF inhibitors in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13255 Sat 24 Mar 2018 08:16:00 AEDT ]]> BRAF and NRAS mutational status are prognostically important in thick and locally advanced cutaneous melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13259 Sat 24 Mar 2018 08:15:59 AEDT ]]> Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13256 Sat 24 Mar 2018 08:15:59 AEDT ]]> CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13251 Sat 24 Mar 2018 08:15:58 AEDT ]]> Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase A regulates PI3K/Akt signaling in human melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13253 Sat 24 Mar 2018 08:15:58 AEDT ]]>